Janux Therapeutics, Inc. Operating Income Loss

• Janux Therapeutics, Inc. showed a decrease of -59.5% in Operating Income Loss from 2024 to 2025.
• This data is from Janux Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Janux Therapeutics, Inc.'s Operating Income Loss has declined by 3,155.6%.
• Historical annual values: Fiscal year 2025: -$157.67 million | Fiscal year 2024: -$98.85 million | Fiscal year 2023: -$72.98 million | Fiscal year 2022: -$67.09 million | Fiscal year 2021: -$32.93 million | Fiscal year 2020: -$4.84 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026